Logo image of COCP

COCRYSTAL PHARMA INC (COCP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:COCP - US19188J4094 - Common Stock

1.01 USD
+0.07 (+7.25%)
Last: 11/26/2025, 8:24:09 PM
Fundamental Rating

2

Overall COCP gets a fundamental rating of 2 out of 10. We evaluated COCP against 192 industry peers in the Pharmaceuticals industry. COCP has a great financial health rating, but its profitability evaluates not so good. COCP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year COCP has reported negative net income.
COCP had a negative operating cash flow in the past year.
COCP had negative earnings in each of the past 5 years.
COCP had a negative operating cash flow in each of the past 5 years.
COCP Yearly Net Income VS EBIT VS OCF VS FCFCOCP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

COCP has a worse Return On Assets (-92.58%) than 75.52% of its industry peers.
The Return On Equity of COCP (-126.11%) is worse than 65.63% of its industry peers.
Industry RankSector Rank
ROA -92.58%
ROE -126.11%
ROIC N/A
ROA(3y)-95.52%
ROA(5y)-64.44%
ROE(3y)-118.44%
ROE(5y)-78.4%
ROIC(3y)N/A
ROIC(5y)N/A
COCP Yearly ROA, ROE, ROICCOCP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

COCP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COCP Yearly Profit, Operating, Gross MarginsCOCP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for COCP remains at a similar level compared to 1 year ago.
The number of shares outstanding for COCP has been increased compared to 5 years ago.
There is no outstanding debt for COCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
COCP Yearly Shares OutstandingCOCP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
COCP Yearly Total Debt VS Total AssetsCOCP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

COCP has an Altman-Z score of -44.79. This is a bad value and indicates that COCP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -44.79, COCP is doing worse than 91.67% of the companies in the same industry.
There is no outstanding debt for COCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -44.79
ROIC/WACCN/A
WACCN/A
COCP Yearly LT Debt VS Equity VS FCFCOCP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 5.78 indicates that COCP has no problem at all paying its short term obligations.
COCP has a better Current ratio (5.78) than 69.27% of its industry peers.
COCP has a Quick Ratio of 5.78. This indicates that COCP is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 5.78, COCP is doing good in the industry, outperforming 69.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.78
Quick Ratio 5.78
COCP Yearly Current Assets VS Current LiabilitesCOCP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

COCP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.19%, which is quite impressive.
EPS 1Y (TTM)49.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.72% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.46%
EPS Next 2Y21.78%
EPS Next 3Y10.72%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
COCP Yearly Revenue VS EstimatesCOCP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2019 2020 2M 4M 6M
COCP Yearly EPS VS EstimatesCOCP Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for COCP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COCP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COCP Price Earnings VS Forward Price EarningsCOCP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COCP Per share dataCOCP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.78%
EPS Next 3Y10.72%

More info and screens

0

5. Dividend

5.1 Amount

COCP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COCRYSTAL PHARMA INC

NASDAQ:COCP (11/26/2025, 8:24:09 PM)

1.01

+0.07 (+7.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners5.27%
Inst Owner Change-3.14%
Ins Owners13.21%
Ins Owner Change1.16%
Market Cap13.92M
Revenue(TTM)N/A
Net Income(TTM)-9.67M
Analysts82.5
Price Target8.16 (707.92%)
Short Float %2.81%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.97%
Min EPS beat(2)11.3%
Max EPS beat(2)34.64%
EPS beat(4)4
Avg EPS beat(4)35.52%
Min EPS beat(4)11.3%
Max EPS beat(4)55.35%
EPS beat(8)7
Avg EPS beat(8)25.71%
EPS beat(12)11
Avg EPS beat(12)24.45%
EPS beat(16)12
Avg EPS beat(16)-14.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.29%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)28.57%
EPS NY rev (1m)0%
EPS NY rev (3m)22.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.81
P/tB 1.81
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0
BVpS0.56
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -92.58%
ROE -126.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.52%
ROA(5y)-64.44%
ROE(3y)-118.44%
ROE(5y)-78.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.78
Quick Ratio 5.78
Altman-Z -44.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)35.21%
Cap/Depr(5y)56.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.22%
EPS Next Y51.46%
EPS Next 2Y21.78%
EPS Next 3Y10.72%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y51.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.79%
OCF growth 3YN/A
OCF growth 5YN/A

COCRYSTAL PHARMA INC / COCP FAQ

Can you provide the ChartMill fundamental rating for COCRYSTAL PHARMA INC?

ChartMill assigns a fundamental rating of 2 / 10 to COCP.


What is the valuation status of COCRYSTAL PHARMA INC (COCP) stock?

ChartMill assigns a valuation rating of 0 / 10 to COCRYSTAL PHARMA INC (COCP). This can be considered as Overvalued.


How profitable is COCRYSTAL PHARMA INC (COCP) stock?

COCRYSTAL PHARMA INC (COCP) has a profitability rating of 0 / 10.


Can you provide the financial health for COCP stock?

The financial health rating of COCRYSTAL PHARMA INC (COCP) is 7 / 10.